89583-07-3

Basic information

• Product Name: 2-(4-Morpholine)ethyl bromide
• Synonyms: 2-(4-MORPHOLINE)ETHYL BROMIDE;2-MORPHOLINOETHYL BROMIDE;Morpholine, 4-(2-broMoethyl)-;4-(2-broMoethyl)Morpholine
• CAS NO: 89583-07-3
• Molecular Formula: C₆H₁₂BrNO
• Molecular Weight: 194.07
• Product Categories: pharmacetical
• Mol File: 89583-07-3.mol

Chemical Properties

• Boiling Point: 219.9 °C at 760 mmHg
• Flash Point: 86.8 °C
• Appearance: /
• Density: 1.393g/cm³
• Vapor Pressure: 0.116mmHg at 25°C
• Refractive Index: 1.495
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 5.90±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Morpholine)ethyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Morpholine)ethyl bromide(89583-07-3)
• EPA Substance Registry System: 2-(4-Morpholine)ethyl bromide(89583-07-3)

Safety Data

• Hazardous Substances Data: 89583-07-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Morpholine)ethyl bromide is used as a synthetic intermediate for the production of various pharmaceutical compounds. Its reactivity allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(4-Morpholine)ethyl bromide is utilized as a key component in the synthesis of pesticides and other crop protection agents. Its role in these formulations helps to enhance the effectiveness of these products in protecting crops from pests and diseases.
Used in Chemical Research:
2-(4-Morpholine)ethyl bromide is also employed as a research chemical, enabling scientists to explore its properties and potential applications in various chemical reactions. This contributes to the advancement of knowledge in the field of chemistry and the discovery of new compounds with beneficial properties.

InChI:InChI=1/C6H12BrNO/c7-1-2-8-3-5-9-6-4-8/h1-6H2

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 102-71-6 triethanolamine 
• 110-54-3 hexane 
• 558-13-4 carbon tetrabromide 
• 110-91-8 morpholine 
• 106-93-4 ethylene dibromide 
• 10035-10-6 hydrogen bromide 
• 25114-70-9 triethanolammonium bromide 

Downstream Products

• 2154-24-7 N-(2-hydrazinoethyl)morpholine 
• 503039-38-1 4-[6-(2-Morpholin-4-yl-ethylamino)-benzothiazol-2-ylsulfanylmethyl]-benzoic Acid Methyl Ester 
• 660395-39-1 4-(2-azido-ethyl)-morpholine 
• 92623-83-1 pravadoline 
• 1152961-27-7 1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-ylamine 
• 71320-77-9 moclobemide 

Relevant articles and documents

Lipid compound and composition thereof

The invention relates to a lipid compound and a composition thereof, a lipid nanoparticle containing the composition, a preparation method of the composition and application of the composition in drug delivery.

triAZOLOtriAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

Cationic lipid molecule, and application thereof in nucleic acid delivery

The present invention discloses a cationic lipid molecule, and an application thereof in nucleic acid delivery. The structural formula of the cationic lipid molecule is represented by formula i. The invention further provides a cationic liposome, a lipid compound, a reagent, a kit, a preparation and a medicinal composition based on the cationic lipid molecule. The cationic lipid molecule has the advantages of simple synthesis process and good stability, and the cationic liposome has a high efficiency (characterized by high transfection efficiency) and a low toxicity, is stable and uniform, is easy to prepare, and can be used for transferring various cell lines. The cationic lipid molecule has excellent transitivity, and can efficiently deliver active substances (such as exemplary siRNA) omto cells (such as exemplary lung cancer cells), tissues and organs to achieve efficient regulation of the active substances. The problem that the toxicity and the transfer efficiency of cationic liposome existing in the prior art are low is solved.

Cross-Electrophile Coupling of Vinyl Halides with Alkyl Halides

An improved method for the reductive coupling of aryl and vinyl bromides with alkyl halides that gave high yields for a variety of substrates at room temperature with a low (2.5 to 0.5 mol %) catalyst loading is presented. Under the optimized conditions, difficult substrates, such as unhindered alkenyl bromides, can be coupled to give the desired olefins with minimal diene formation and good stereoretention. These improved conditions also worked well for aryl bromides. For example, a gram-scale reaction was demonstrated with 0.5 mol % catalyst loading, whereas reactions at 10 mol % catalyst loading completed in as little as 20 minutes. Finally, a low-cost single-component pre-catalyst, (bpy)NiI2 (bpy=2,2′-bipyridine) that is both air- and moisture-stable over a period of months was introduced.

NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS

(I)The invention relates to novel novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and diso

Thiazolyl-Benzimidazoles

The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

Integrase inhibitors

Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Substituted amine derivatives, their production and use

Substituted amino derivatives represented by the formula: STR1 wherein R1 and R2 each stand for an acyclic hydrocarbon residue or an alicyclic hydrocarbon residue; R3 and R4 each stand for hydrogen or a hydrocarbon residue optionally containing hetero-atom(s); A stands for a carbon chain having two or more carbon atoms optionally containing ether linkage or sulfide linkage, which may be substituted and which may per se form a ring; X1 and X2 each stand for oxygen atom or sulfur atom; and Y stands for amino group or an organic residue bonded through nitrogen atom, which may form a ring by combining with a carbon atom constituting A; and their salts have anti-arrhythmic activity and are useful for prevention and treatment of a variety of arrhythmias.